Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

TOI The Oncology Institute, Inc. Common Stock
$6.13 -5.18% -0.34
Notify me if price changes either direction
Interactive Brokers Logotype

Buy TOI stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 612.9M
Enterprise value 587.5M
Trailing PE -11.351852063779
Forward PE -32.0625
PEG Ratio 0.24325397279527
Enterprise to EBITDA -22.677
Enterprise to revenue 1.077
Price to book MRQ -25.350528372843
Price to sales TTM 0.9398064

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 545.8M
EBITDA -25909000
Diluted EPS TTM -0.35
Total Cash (MRQ) 30.3M
Current ratio (MRQ) 1.473
Operating Cash Flow (TTM) -21814000

TOI trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent TOI News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.